middle.news
Actinogen Surpasses Recruitment Target, Eyes November for XanaMIA Trial Results
10:32am on Friday 30th of January, 2026 AEDT
•
Biotechnology
Read Story
Actinogen Surpasses Recruitment Target, Eyes November for XanaMIA Trial Results
10:32am on Friday 30th of January, 2026 AEDT
Key Points
XanaMIA trial enrols 247 participants, exceeding original target
Independent Data Monitoring Committee endorses trial continuation post-interim analysis
Open-label extension phase to start in Q1 2026 with all participants receiving Xanamem
Manufacturing of Xanamem tablets completed for extension phase
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACTINOGEN MEDICAL (ASX:ACW)
OPEN ARTICLE